FDA Clears Application for NUV-1511 for Advanced Solid Tumors

News
Article

Plans have been put in place to launch a phase 1/2 study assessing NUV-1511 in a population of patients with advanced solid tumors.

A phase 1/2 dose escalation study, which is expected to launch in 2024, will determine the safety, tolerability, and clinical efficacy of NUV-1511 in a population diagnosed with advanced solid tumors that have progressed on or following treatment with fam-trastuzumab deruxtecan-nxki (Enhertu) and/or sacituzumab govitecan-hziy (Trodelvy).

A phase 1/2 dose escalation study, which is expected to launch in 2024, will determine the safety, tolerability, and clinical efficacy of NUV-1511 in a population diagnosed with advanced solid tumors that have progressed on or following treatment with fam-trastuzumab deruxtecan-nxki (Enhertu) and/or sacituzumab govitecan-hziy (Trodelvy).

The FDA has cleared an investigational new drug (IND) application for novel drug-drug conjugate (DDC) platform NUV-1511 for the treatment of advanced solid malignancies, according to a press release from Nuvation Bio.1

A phase 1/2 dose escalation study, which is expected to launch in 2024, will determine the safety, tolerability, and clinical efficacy of NUV-1511 in a population diagnosed with advanced solid tumors that have progressed on or following treatment with fam-trastuzumab deruxtecan-nxki (Enhertu) and/or sacituzumab govitecan-hziy (Trodelvy). In particular, the study will include patients with HER2-negative metastatic breast cancer, metastatic castration-resistant prostate cancer (CRPC), pancreatic cancer, and platinum-resistant ovarian cancer.

“This IND clearance expands our clinical pipeline and validates the approach of our proprietary DDC platform to design potent oncology-focused chimeric small molecules [that] combine tumor-targeting specificity with the anti-cancer activity of known oncology agents,” David Hung, MD, founder, president, and chief executive officer at Nuvation Bio, said in the press release.1 “We believe NUV-1511 has the potential to provide favorable clinical benefit for patients with various solid tumors and we look forward to initiating the phase 1/2 study.”

The DDC platform uses a novel therapeutic approach and was designed to selectively deliver robust anti-cancer agents to cancer cells and generate greater toxicity in target tumor cells rather than healthy non-target cells.2 The platform will allow investigators to use anti-cancer therapies to conjugate tissue-selective, targeted small molecules.

Nuvation Bio also submitted an IND for a BD2 selective oral small molecule bromodomain and extra-terminal inhibitor NUV-868 for a solid tumor indication in January 2022.3 This indication included those with ovarian cancer, pancreatic cancer, metastatic CRPC, and triple-negative breast cancer.

The agent inhibits BRD4, which belongs to the BET family and is known to epigenetically regulate proteins responsible for tumor growth. NUV-868 was designed as a more selective inhibitor of BD2 rather than BD1 to limit common toxicities seen with other BRD4 inhibitors such as gastrointestinal and bone marrow adverse effects.

Although NUV-868 appeared to be more selective for BD2 vs BD1 in preclinical studies, investigators intend to assess the single agent as part of a phase 1/2 study in those with advanced solid tumors. This will be followed by a phase 2b study to further assess safety and efficacy after determining the recommended phase 2 dose, as well as a phase 2 single-agent study in those with metastatic CRPC.

“The clearance of our IND application for NUV-868 is an important milestone for Nuvation Bio as it marks the fourth IND in the last 14 months across our deep pipeline of innovative cancer therapeutics targeting multiple tumor types,” Hung said at the time of the press release.3 “We are encouraged by the selectivity and potentially improved tolerability demonstrated by NUV-868 in preclinical studies, and we look forward to advancing the program into phase 1 development in mid-2022.”

References

  1. Nuvation Bio announces FDA clearance of investigational new drug application for NUV-1511 for the treatment of advanced solid tumors. News release. Nuvation Bio. January 8, 2024. Accessed January 8, 2024. https://bit.ly/3tNwK7A
  2. Pipeline. Nuvation Bio. Accessed January 11, 2023. https://bit.ly/3HfBMNh
  3. Nuvation Bio announces FDA clearance of investigational new drug application for NUV-868 for the treatment of advanced solid tumors. News release. Nuvation Bio. January 20, 2022. Accessed January 11, 2024. https://bit.ly/41WbCZr
Related Videos
Cancer vaccines are a “cross-cutting approach” that may be applicable across several cancer types, according to Catherine J. Wu, MD.
mRNA may be a potential modality for developing cancer-based vaccines, according to Catherine J. Wu, MD.
Analyzing the KRAS mutation across various cancer types may be a worthwhile target when using a cancer vaccine or immunotherapy, says Catherine J. Wu, MD.
The AACR Health Disparities Report highlights the changes needed to achieve health equity for patients with cancer.
Robert A. Winn, MD, gives insight into how institutions and community practices can improve access to cancer care.
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Related Content
Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Cancer Symptom Improvements Occur With Telehealth Exercise Program

April 27th 2024
Article

Additional research may be necessary to validate the efficacy of telehealth interventions in clinical activities for patients with cancer.

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Striving for Health Care Equity by Closing the Cancer Care Gap

Striving for Health Care Equity by Closing the Cancer Care Gap

April 18th 2024
Article

“If you were to ask me what the 1 magic thing would be, it would be that we would adopt a concept of 1 team, one fight nationally, and that we would be able to have our structures and our coordination of care.”

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Addressing Rising Cancer Incidence and Burden in Younger Populations

March 11th 2024
Podcast

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

FDA Grants Accelerated Approval to T-DXd in Advanced HER2+ Solid Tumors

April 5th 2024
Article

Results from 3 DESTINY trials led to the accelerated approval of fam-trastuzumab deruxtecan-nxki for patients with unresectable or metastatic HER2-positive solid tumors.

Further research may be needed to help determine the underlying mechanisms of polybrominated diphenyl ether exposure contributing to the risk of cancer-related mortality.

PBDE Exposure Confers Significant Cancer Mortality Risk

April 4th 2024
Article

Further research may be needed to help determine the underlying mechanisms of polybrominated diphenyl ether exposure contributing to the risk of cancer-related mortality.